JC-171|cas:2112809-98-8|西域试剂

JC-171,99.71%

产品编号：Bellancom-117432| CAS NO：2112809-98-8| 分子式：C₁₆H₁₇ClN₂O₅S| 分子量：384.83

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-117432	￥3000.00	杭州北京（现货）
Bellancom-117432	￥5000.00	杭州北京（现货）
Bellancom-117432	￥15000.00	杭州北京（现货）
Bellancom-117432	￥22500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

JC-171

产品介绍

JC-171 是选择性的 NLRP3 炎症小体抑制剂，抑制 LPS/ATP 诱导的巨噬细胞释放 IL-1β 的 IC₅₀ 值为 8.45 μM。

生物活性

JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC₅₀ of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages.

体外研究

JC-171 (0-100 μM) blocks NLRP3 inflammasome activation and IL-1β production in primary macrophages dose dependently.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	J774A.1 murine macrophage cells
Concentration:	0-100 μM.
Incubation Time:	0.5 h (before LPS (1 μg/mL) treatment for 4.5 h).
Result:	Inhibited the release of IL-1β in J774A.1 cells upon stimulation with LPS/ATP.

体内研究
(In Vivo)

JC-171 treatment delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE) in mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice immunized subcutaneously with 200 μg Myelin oligodendrocyte glycoprotein (MOG) _35–55 peptide emulsified in Complete Freund’s Adjuvant (CFA) on day 0 followed by injection of 200 ng of pertussis toxin.
Dosage:	100 mg/kg, 10 mg/kg.
Administration:	IP days 0, 1 and 2; and every other days thereafter (100 mg/kg). Initiated when the clinical scores of individual mice have reached 1 (flaccid tail), and given every other day (10 mg/kg).
Result:	Efficiently suppressed EAE progression compared with vehicle treatment. Resulted in a substantial decrease in the frequency of MOG_35–55-specific Th17 cells in the spleens and spinal cords of EAE mice.

体内研究

JC-171 treatment delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE) in mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice immunized subcutaneously with 200 μg Myelin oligodendrocyte glycoprotein (MOG) _35–55 peptide emulsified in Complete Freund’s Adjuvant (CFA) on day 0 followed by injection of 200 ng of pertussis toxin.
Dosage:	100 mg/kg, 10 mg/kg.
Administration:	IP days 0, 1 and 2; and every other days thereafter (100 mg/kg). Initiated when the clinical scores of individual mice have reached 1 (flaccid tail), and given every other day (10 mg/kg).
Result:	Efficiently suppressed EAE progression compared with vehicle treatment. Resulted in a substantial decrease in the frequency of MOG_35–55-specific Th17 cells in the spleens and spinal cords of EAE mice.

体内研究

JC-171 treatment delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE) in mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice immunized subcutaneously with 200 μg Myelin oligodendrocyte glycoprotein (MOG) _35–55 peptide emulsified in Complete Freund’s Adjuvant (CFA) on day 0 followed by injection of 200 ng of pertussis toxin.
Dosage:	100 mg/kg, 10 mg/kg.
Administration:	IP days 0, 1 and 2; and every other days thereafter (100 mg/kg). Initiated when the clinical scores of individual mice have reached 1 (flaccid tail), and given every other day (10 mg/kg).
Result:	Efficiently suppressed EAE progression compared with vehicle treatment. Resulted in a substantial decrease in the frequency of MOG_35–55-specific Th17 cells in the spleens and spinal cords of EAE mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (649.64 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5986 mL	12.9928 mL	25.9855 mL
5 mM	0.5197 mL	2.5986 mL	5.1971 mL
10 mM	0.2599 mL	1.2993 mL	2.5986 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.40 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.40 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.40 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.40 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。